Disease Landscape Assessment
Map an indication from a single query. Synapse aggregates validated targets, the competitive treatment landscape, clinical trial activity, biomarker coverage, genetic basis, and unmet need into a structured landscape report. Enter a disease name and get a scored, source-attributed view of the entire indication.
Deliverables
Validated target list
All validated targets for the indication, ranked by evidence strength with mechanism-of-action annotations. Each target entry includes its disease association score, the sources supporting it, and whether the evidence comes from clinical, preclinical, or genetic data. For the GLP1R landscape, 286 disease associations were scored, with hypertension and social isolation reaching the maximum score of 1.00.
Treatment landscape
Drugs grouped by treatment line and development phase, cross-referenced against trial data. The landscape covers 317 clinical trials across Phase 1-4, with status breakdowns showing which are recruiting, active, or completed. Drug-indication relationships are mapped so you can see exactly which compounds target which conditions and how far along they are.
Unmet need assessment
An integrated score combining epidemiology data, treatment gaps, and genetic underpinnings. This identifies indications where existing treatments are insufficient and where the target biology suggests a viable intervention. The assessment highlights whitespace opportunities: conditions with strong biological rationale but thin clinical development.
Evaluate indication attractiveness and identify whitespace opportunities. Indications with high unmet need, strong target-disease associations, and limited competition represent the best strategic opportunities.
GLP1R disease landscape: associations, trials, and competitive field
| Drug | Score | Papers |
|---|---|---|
| Exenatide | 1.00 | 29 |
| Semaglutide | 0.95 | 24 |
| Tirzepatide | 0.92 | 18 |
| Dulaglutide | 0.90 | 21 |
| Liraglutide | 0.88 | 26 |
| Lixisenatide | 0.75 | 12 |
| Albiglutide | 0.70 | 8 |
CROSS-THERAPEUTIC-AREA DISEASE COMPARISON
| Target | Area | Top Disease | Score | Diseases | Trials |
|---|---|---|---|---|---|
| GLP1R | Metabolic | Hypertension | 1.00 | 286 | 317 |
| EGFR | Oncology | NSCLC | 0.77 | 148 | 2,293 |
| IL13 | Allergy/Inflammation | Atopic Asthma | 1.00 | 143 | 73 |
Methodology
Map validated targets from literature and registries
Synapse aggregates target-disease associations from literature, trial registries, and genetic databases. Each association is scored by evidence strength, replication, and directional consistency.
Score targets by evidence strength
Targets are ranked using a composite score that weights source quality, replication count, and evidence type (genetic, clinical, preclinical). Mechanism-of-action annotations provide biological context.
Build treatment landscape
Drugs are grouped by treatment line and mapped across development phases. Trial data from ClinicalTrials.gov provides enrollment, status, sponsor, and primary endpoint information for each entry.
Compute unmet need score
Epidemiology data, treatment gaps, and genetic underpinnings are integrated into a composite unmet need metric. High scores indicate conditions where current treatments are insufficient despite biological rationale.
Identify whitespace opportunities
The platform highlights indications where evidence is strong but clinical development is sparse, representing strategic opportunities for entry. Conversely, it flags crowded areas where differentiation will be challenging.
Target personas
Indication strategist
Assess the competitive and scientific landscape for any indication to inform portfolio decisions.
Market access analyst
Understand the treatment landscape, unmet need, and competitive dynamics before market entry planning.
Portfolio lead
Compare indications by evidence strength, competitive density, and strategic fit to allocate development resources.
Explore more
Ready to see your own data analyzed?
Tell us what you're working on. We can show you what the output would look like.